Ultraviolet Light Therapy for Systemic Lupus Erythematosus

National Center for Research Resources (NCRR)

Status and phase: Unknown; Phase 2

Conditions: Systemic Lupus Erythematosus

Treatments: Procedure: ultraviolet A-1 light treatment

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00004375

LSUMC-1765

LSUMC-910067

NCRR-M01RR05096-0002

Details and patient eligibility

About

OBJECTIVES:

I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.

Full description

PROTOCOL OUTLINE:

Treatment with ultraviolet A-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. The dose and frequency are progressively decreased over the next 9 weeks.

Sex: All

Ages: 15 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Patients ages 15 to 70 with symptomatic systemic lupus erythematosus meeting American Rheumatism Association criteria and normal controls

--Prior/Concurrent Therapy--

No requirement for tetracycline or other photosensitizing drugs